<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123718</url>
  </required_header>
  <id_info>
    <org_study_id>HDMTX</org_study_id>
    <nct_id>NCT03123718</nct_id>
  </id_info>
  <brief_title>High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL</brief_title>
  <official_title>Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consortium for Improving Survival of Lymphoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outcome of patients with central nervous system (CNS) relapse in DLBCL is poor, with
      median survival times of 2-5 months. This fatal prognosis necessitates CNS prevention in a
      subgroup of patients with a high risk of CNS relapse.

      Intrathecal methotrexate (ITMTX) has traditionally been used, although its efficacy for CNS
      prophylaxis is contradictory. High-dose intravenous methotrexate (IVMTX) has been suggested
      as an alternative approach. Considering the lack of evidence supporting the role of ITMTX,
      the investigators propose to compare the efficacy of ITMTX and IVMTX for prophylaxis of CNS
      relapse in a subgroup of patients with DLBCL at a high risk for CNS relapse.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of CNS relapse</measure>
    <time_frame>2 year</time_frame>
    <description>The rate of relapse will be analyzed by the cumulative incidence method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 year</time_frame>
    <description>Toxicity will be graded according to NCI-CTCAE v.4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 year</time_frame>
    <description>PFS will be calculated from randomization to the date of CNS relapse and/or systemic disease progression, death, or last follow-up, as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Intrathecal Methotrexate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Intravenous Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal methotrexate</intervention_name>
    <description>Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.</description>
    <arm_group_label>Intrathecal Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose intravenous methotrexate</intervention_name>
    <description>Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged &gt;70 years.</description>
    <arm_group_label>High-dose Intravenous Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 years &lt;80

          -  Newly diagnosed, histologically confirmed DLBCL

          -  High-risk of CNS recurrence at diagnosis:

               1. Age-adjusted IPI (aaIPI) ≥2 or IPI ≥4 with extranodal involvement of &gt;1 site plus
                  serum lactate dehydrogenase (LDH) &gt; normal OR

               2. Involvement of high-risk locations: bone marrow, nasal or paranasal sinuses,
                  testis, epidural disease (paravertebral or vertebra), breast, adrenal or kidney

          -  Estimated life expectancy of more than 90 days

          -  Performance status (ECOG) ≤ 2

          -  Written informed consent

        Exclusion Criteria:

          -  Psychiatric or mental disorder which make the patient unable to give an informed
             consent and/or adhere to the protocol

          -  DLBCL or following subtypes:

               1. Primary mediastinal large B-cell lymphoma

               2. Grey zone lymphoma)

               3. Primary cutaneous DLBCL

          -  Previous immunochemotherapeutic treatment for DLBCL other than short-term use of
             corticosteroids (≤ 8 days before randomization)

          -  Previous radiotherapy

          -  CNS involvement of DLBCL at diagnosis

          -  HIV positive

          -  Any contraindication for application of RCHOP or high dose methotrexate

          -  Any of following laboratory results

               1. Absolute neutrophil count &lt; 1,500 cells/mm3 (1.5 x 109/L),

               2. Platelet count &lt; 100,000/mm3 (100 x 109/L), or &lt; 75,000 /mm3 in patients with
                  bone marrow involvement,

               3. Serum aspartate transaminase or serum alanine transaminase ≥3.0 x upper limit of
                  normal (ULN),

               4. Serum total bilirubin &gt; 2 x ULN (with the exception of hemolytic anemia),

          -  Serum creatinine &gt;2.0 x ULN or creatinine clearance &lt;50 mL/min

          -  Active cancer except curable basal cell carcinoma, cervical cancer in situ, and/or
             papillary thyroid cancer during the last five years

          -  Ejection fraction &lt; 45% on echocardiography

          -  Uncontrolled active hepatitis

          -  Pregnancy or breast-feeding

          -  Men and women of reproductive potential no agreeing to use an acceptable method of
             birth control during treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deok-Hwan Yang</last_name>
    <phone>+82-61-379-7636</phone>
    <email>drydh1685@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seung-Ah Yahng</last_name>
    <phone>+82-32-280-5893</phone>
    <email>saymd@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Deok-Hwan Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>methotrexate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

